Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2018

View Archived Issues

FDA grants orphan drug designation to BN-Brachyury as treatment for chordoma

Refuge Biotechnologies completes series B financing

Azitra raises new financing to advance pipeline

Coherus BioSciences announces re-submission of BLA for CHS-1701

Daiichi Sankyo profiles highlights of fourth quarter of fiscal 2017

Abbisko presents novel candidates with promising preclinical profiles

Phase I results reported for analgesic CCR2 antagonist CNTX-6970

RBH-61, a dual SEH/PDE inhibitor for inflammatory pain

FDA grants two fast track designations for 5F9

Ocular Therapeutix doses first patient in phase I clinical trial of OTX-TIC

Bristol-Myers Squibb presents new apelin receptor agonists

Ferring Pharmaceuticals acquires option to commercialize nadofaragene firadenovec/Syn3

AbbVie divulges novel BRD4 inhibitors

Jiangsu Hengrui Medicine and collaborator disclose TGFR-1 inhibitors

Sanofi reviews key events of first quarter 2018

Phase III trial of ranibizumab biosimilar FYB-201 meets primary endpoint

RTI International discovers new APLNR agonists

Dong-A Socio Holdings identifies Mer inhibitors

Phase I trial begins of CS-1002 for advanced solid tumors begins in Australia

FDA joint advisory committee meeting recommends against stannsoporfin

Moderna Therapeutics and Merck & Co. expand cancer collaboration

New albumin-binding compounds from CytRx show antitumor activity in xenograft models

FDA approves AndexXa to reverse factor Xa inhibitors

Altum Pharmaceuticals acquires Lexi Pharma

First patient dosed in phase II study of AG-10 in ATTR cardiomyopathy

DLK inhibitor shows promising data in vivo

Casma Therapeutics launched to develop breakthrough therapies by boosting autophagy

OTL-200 receives rare pediatric disease designation from the FDA

EMA validates type II variation application for Opdivo plus Yervoy in first-line NSCLC

Sarepta partners with Myonexus to advance gene therapies for limb-girdle muscular dystrophy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...